Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20676
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoukos, D. H.en
dc.date.accessioned2015-11-24T19:09:14Z-
dc.date.available2015-11-24T19:09:14Z-
dc.identifier.issn1473-1150-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20676-
dc.rightsDefault Licence-
dc.subjectAntibodies, Monoclonal/*pharmacologyen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntineoplastic Agents/*pharmacologyen
dc.subjectBreast Neoplasms/*geneticsen
dc.subjectFemaleen
dc.subjectGene Expression Profilingen
dc.subjectGene Regulatory Networks/*geneticsen
dc.subjectGenome, Human/*geneticsen
dc.subjectGenotypeen
dc.subjectHumansen
dc.subjectIndividualized Medicineen
dc.subjectMaleen
dc.subjectMutationen
dc.subjectStomach Neoplasms/*geneticsen
dc.subjectTumor Markers, Biological/geneticsen
dc.titleTrastuzumab and beyond: sequencing cancer genomes and predicting molecular networksen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1038/tpj.2010.81-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20975737-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractLife diversity can now be clearly explored with the next-generation DNA sequencing technology, allowing the discovery of genetic variants among individuals, patients and tumors. However, beyond causal mutations catalog completion, systems medicine is essential to link genotype to phenotypic cancer diversity towards personalized medicine. Despite advances with traditional single genes molecular research, including rare mutations in BRCA1/2 and CDH1 for primary prevention and trastuzumab for treating HER2-overexpressing breast and gastric tumors, overall, treatment failure and death rates are still alarmingly high. Revolution in sequencing reveals that, now both a huge number and widespread variability of driver mutations, including single-nucleotide polymorphisms, genomic rearrangements and copy-number changes involved in breast cancer development. All these genetic alterations result in a heterogeneous deregulation of signaling pathways, including EGFR, HER2, VEGF, Wnt/Notch, TGF and others.Cancer initiation, progression and metastases are driven by complex molecular networks rather than linear genotype-phenotype relationship. Therefore, clinical expectations by traditional molecular research strategies targeting single genes and single signaling pathways are likely minimal. This review discusses the necessity of molecular networks modeling to understand complex gene-gene, protein-protein and gene-environment interactions. Moreover, the potential of systems clinico-biological approaches to predict intracellular signaling pathways components networks and cancer heterogeneous cells within an individual tumor is described. A flowchart specific for three steps in cancer evolution separately tumorigenesis, early-stage and advanced-stage breast cancer is presented. Using reverse engineering starting with the integration of available established clinical, environmental, treatment and oncological outcomes (survival and death) data and then the still incomplete but progressively accumulating genotypic data into computational networks modeling may lead to bionetworks-based discovery of robust biomarkers and highly effective cancer drugs targets.en
heal.journalNamePharmacogenomics Jen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons